# A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

> **NCT02204345** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 12 (actual)

## Conditions studied

- Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** RO5479599

## Key facts

- **NCT ID:** NCT02204345
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204345, "A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02204345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*